语言

China

中国 地图

查看印度查看巴西

省份

请在下方的农业企业信息库中进行搜索

行业

位置: 中国 - Zhejiang - 行业- - ZHEJIANG JIUZHOU PHARMACEUTICAL CO.,LTD.

  • 公司名称: ZHEJIANG JIUZHOU PHARMACEUTICAL CO.,LTD.

  • 联系人:

  • 电话:

  • 行业: 实验室 Laboratory

  • 地址: No.99 Waisha Road, Jiaojiang Taizhou city, Zhejiang, 318000 China

  • E-mail:

  • Company category:

  • 员工数量:

  • 网站地址:

  • Last updated: 2026-03-23

纳税人编号:

营收:

公司介绍 ：

Jiuzhou Pharma is a global CDMO specialising in small-molecule and peptide API development, process optimisation, analytical services, and GMP manufacturing. Our laboratories provide route-scouting, scalable process development, solid-state characterisation, and full analytical method development and validation services. We support advanced chemistry including asymmetric catalysis, flow chemistry, fluorination, enzymatic catalysis, cryogenic and high-pressure reactions, and HPAPI development (OEB4/OEB5). Our peptide laboratories offer SPPS and LPPS synthesis, purification, characterisation, and lyophilisation for research through development, to full-scale commercial supply. Solid-state capabilities include polymorph screening, crystallisation development, and salt-form selection. Jiuzhou’s GMP facilities enable seamless scale-up from milligram to commercial tonnes, supported by a full CMC and regulatory team experienced with global filings (DMF, CEP, ANDA, IND). We also provide early formulation development for oral solid dose and semi-solid products. We offer integrated DS–DP services, rapid technology transfer, cost-efficient manufacturing in a mature GMP network, and reliable global supply to more than 90 countries. State of the art Process R & D facility at our Konstanz site in Germany. Small but rapidly growing team of top European PhD Chemists. High -throughput and -data workflow makes this team highly competitive and fast. Particular expertise in small molecule new route identification and development, and route optimisation. Jiuzhou Pharma’s ESG strategy is anchored in science-based GHG reduction targets, renewable energy adoption, supply-chain engagement, robust governance, and international benchmarks and recognitions. Our framework reflects best practices in the pharmaceutical sector for environmental and social responsibility. As evidenced by external independent recognition: Inclusion in the FTSE4Good Index, improved ESG ratings from the London Stock Exchange Group, EcoVadis Gold Medal, AA rating from Wind, validation of GHG emission targets by the SBTi.

公司产品：